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Abstract
Preservation of b-cell function as measured by stimulated C-peptide has recently been accepted as a therapeutic target for
subjects with newly diagnosed type 1 diabetes. In recently completed studies conducted by the Type 1 Diabetes Trial
Network (TrialNet), repeated 2-hour Mixed Meal Tolerance Tests (MMTT) were obtained for up to 24 months from 156
subjects with up to 3 months duration of type 1 diabetes at the time of study enrollment. These data provide the
information needed to more accurately determine the sample size needed for future studies of the effects of new agents on
the 2-hour area under the curve (AUC) of the C-peptide values. The natural log(x), log(x+1) and square-root (
ﬃﬃﬃ
x
p
)
transformations of the AUC were assessed. In general, a transformation of the data is needed to better satisfy the normality
assumptions for commonly used statistical tests. Statistical analysis of the raw and transformed data are provided to
estimate the mean levels over time and the residual variation in untreated subjects that allow sample size calculations for
future studies at either 12 or 24 months of follow-up and among children 8–12 years of age, adolescents (13–17 years) and
adults (18+ years). The sample size needed to detect a given relative (percentage) difference with treatment versus control is
greater at 24 months than at 12 months of follow-up, and differs among age categories. Owing to greater residual variation
among those 13–17 years of age, a larger sample size is required for this age group. Methods are also described for
assessment of sample size for mixtures of subjects among the age categories. Statistical expressions are presented for the
presentation of analyses of log(x+1) and
ﬃﬃﬃ
x
p
transformed values in terms of the original units of measurement (pmol/ml).
Analyses using different transformations are described for the TrialNet study of masked anti-CD20 (rituximab) versus
masked placebo. These results provide the information needed to accurately evaluate the sample size for studies of new
agents to preserve C-peptide levels in newly diagnosed type 1 diabetes.
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Introduction
Type 1 diabetes results from a T-cell mediated progressive
autoimmune destruction of the insulin secreting pancreatic b-cells
[1], and numerous therapeutic targets and agents have been
proposed to ameliorate this process [2] based on a growing
understanding of the underlying mechanisms. The measurement
of C-peptide in response to a stimulus provides a valid and reliable
measure of the effects of therapy on residual b-cell function [3], the
preferred stimulus being a mixed-meal tolerance test [4], as
recognized in the recent FDA guidance on drug development in
newly diagnosed type 1 diabetes [5]. Unfortunately, published
reports from recently completed trials generally do not present the
measures of residual variation and other quantities needed to
guide sample size determination for future trials. The best
available data [3] were based on a pooling of data from prior
published and unpublished studies in subjects with a wide range of
diabetes duration, heterogeneous methods of collection and assays,
and limited follow-up.
The Type 1 Diabetes Trial Network, established by the
National Institute of Diabetes, Digestive and Kidney Diseases,
recently conducted two therapeutic trials in recent onset type 1
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26471diabetes. Herein the available data from these studies are used to
describe the effects of different transformations on the distribu-
tional properties (e.g. normality) of the C-peptide values, and to
evaluate the sample size (or power) for a new study.
Methods
Subjects
The anti-CD20 study [6] enrolled 87 subjects, 81 meeting the
intention-to-treat criteria (52 rituximab, 29 placebo). The results
showed that rituximab significantly preserved b-cell function at the
primary 12-month outcome visit [6]. The analyses herein employ
the 30 placebo treated subjects who completed the 12 month
examination, including an additional placebo subject who had
been excluded from the intention-to-treat cohort because placebo
infusions (double masked) were halted owing to a safety alert.
The MMF/DZB study [7] included 126 subjects randomly
assigned to either mycophenolate mofetil alone or in combination
with daclizumab, or a control group, who were followed for up to
2 years. Therapy was terminated for futility in the spring of 2008
by the external Data and Safety Monitoring Board after observing
virtually no differences in C-peptide levels among the treatment
groups. Further, since the two treated groups in the MMF/DZB
study [7] were no different from placebo, the data from the 126
MMF/DZB study subjects were pooled with the 30 anti-CD20
placebo control group subjects as the basis for the analyses herein.
Methods and Procedures
The MMF/DZB and anti-CD20 studies enrolled male and
female subjects between ages 8–45 within 100 days of diagnosis of
Type 1 diabetes who had at least one islet autoantibody and peak
stimulated C-peptide §0:2 pmol/ml. Stimulated C-peptide values
were obtained during a 2 or 4 hour mixed-meal tolerance test
(MMTT) [4] conducted at baseline, 3, 6, 12, 18 and 24 months.
Only the 2-hour data are employed herein. Over 5 minutes,
participants ingested the Boost liquid oral dietary supplement
(mixed meal, Nestle ´ HealthCare Nutrition, Inc.) dosed relative to
body weight. Basal (fasting) plasma samples were collected
10 minutes prior to the meal (210), just prior to the time of
ingestion (0), and at 15, 30, 60, 90 and 120 minutes thereafter. C-
peptide levels were measured centrally at the b-cell function
laboratory (Seattle, WA). The primary outcome was the area
under the 2-hour curve (AUC) in pmol/ml/120 min computed
using the trapezoidal rule. The corresponding ‘‘ AUC mean’’ in
pmol/ml is obtained as AUC/120 [3,4]. Non-measurable timed
values were set equal to the lower limit of quantification of the
assay before computing the AUC.
Statistical Considerations
Most C-peptide values will fall between 0 and 1 and the
distribution is positively skewed [3]. Thus, scale-contracting trans-
formations were considered. However, the log transformation could
introduce negative skewness because log(x) approaches {? as the
value x approaches zero. This can be corrected by using log(xz1)
[8]. The square-root transformation compresses the distribution of
values w1 and slightly expands the distribution of values between 0
and 1. Both the MMF/DZB and anti-CD20 studies pre-specified that
the primary analyses would employ the log(xz1) values.
Commonly, the primary analysis compares the mean of the C-
peptide values between treatment groups after a period of
treatment such as 12 or 24 months. With normally distributed
errors, the most powerful test is an Analysis of Covariance
(ANCOVA) adjusting for the baseline C-peptide value [9], and
other baseline factors such as age and sex as previously
recommended [3]. Algebraically, this is equivalent to an analysis
using the change from baseline when adjusted for the baseline
value [10]. Herein the analyses of the follow-up AUC mean values
from the 2 hours of the MMTT are presented using the combined
data from the two studies with an adjustment for study (MMF/
DZB versus anti-CD20) and treatment group so as to account for
any chance differences among studies and groups.
ANCOVA assumes normally distributed residuals with constant
variationovertherangeofC-peptidevalues(homoscedasticity).The
residuals were obtained from the regression of each subject’s raw or
transformed variables on age, sex, study and treatmentgroup within
study.The distributionoftheresidualswasevaluatedusingquantile-
quantile plots [11]. The Shapiro-Wilks test [12] assessed departures
from normality. White’s test [13] assessed the assumption of
homoscedasticity (constant error variances among subjects).
For each transformation y~f(x), the mean values and
confidence limits are presented using the inverse transformation
applied to the mean of the transformed values, (y)
{1 , and the
corresponding confidence limits. Thus, for an analysis using
y~log(x), the inverse mean is the geometric mean x~exp(y).
For an analysis using y~log(xz1), the inverse mean is the
geometric-like mean x~exp(y){1. For an analysis using y~
ﬃﬃﬃ
x
p
,
the inverse mean is x~y2.
An analysis using the log-transformed values is readily described
in terms of geometric means and a percentage difference between
groups. The final Results sub-section on Statistical Computations
shows how an analysis using the log(xz1) transformed values can
also be described as a ratio of geometric means, and an analysis
using the
ﬃﬃﬃ
x
p
values can be described as a difference in ordinary
means, both in units of pmol/ml. That section also derives
expressions that can be employed to compute the standard errors
and confidence limits for the inverse transformed means following
an analysis with either the log(xz1) or
ﬃﬃﬃ
x
p
transformations.
Ethical Statement
The anti-CD20 and/or MMF/DZB study protocols and
consent documents were approved by the IRB of Benaroya
Research Institute (Seattle), Children’s Hospital Los Angeles,
Columbia University, The George Washington University,
Indiana University, Institut Feur Diabetes (Munich), Joslin
Diabetes Center, San Raffaele University (Milan), Stanford
University, University of California San Francisco, University of
Colorado, University of Florida, University of Miami, University
of Minnesota, University of Pittsburgh University of Texas
Southwestern Medical School, University of Toronto, and the
University of Washington. Each institution participated in one or
in both studies that generated the data on which this report is
based. All consents were obtained in writing.
Results
Distribution Properties
The characteristics of the subjects in the two studies were
comparable owing to the similar eligibility criteria (Table 1). Of
the complete cohort, 152 (97%) were evaluated at 12 months and
118 (76%) at 24 months, the latter owing to early termination of
the MMF/DZB study. Figure 1 also presents box and whisker
plots of the values over time which show that the distributions are
strongly positively skewed with an elongated right tail.
Figures 2, 3, 4, 5 show the quantile-quantile (Q-Q) plots of the
residuals from an analysis of the raw and the transformed values at
12 and at 24 months adjusted for the baseline value, age, sex, study
(MMF/DZB versus anti-CD20) and treatment group within study.
These plots compare the empirical quantiles (the dots) versus those
Sample Size for Studies in Early Type 1 Diabetes
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observed data is normally distributed when the observed values fall
directly on the line. For both the 12 and 24-month data, the raw
AUC mean values show the most severe departures from
normality with a distribution that is far too peaked and with right
skewness. The ideal normal distribution would in fact have longer
symmetric tails that would fall outside of the range of the observed
values. The log(x) transformation expands the left tail, but too
much so, generating left skewness and does not correct for the
peakedness. The log(xz1) and the
ﬃﬃﬃ
x
p
transformation both
provide a more symmetric and less peaked distribution relative to
the ideal normal.
Table 2 presents the Shapiro-Wilks test and White’s test results.
The Shapiro-Wilks test of normality showed significant departures
from normality for the raw AUC mean values and the log(x)
values at both 12 and 24 months, but not the log(xz1) and
ﬃﬃﬃ
x
p
values (results not shown). At 12 months, White’s test of
homoscedasticity suggested somewhat greater heteroscedasticity
(non-constant error variance) for the log(xz1) values, compara-
ble to that for the raw values, but each measure had similar results
at 24 months.
These analyses suggest that the distributional assumptions for an
ANCOVA test of means at 12 or 24 months are adequately met
using either the log(xz1) or using the
ﬃﬃﬃ
x
p
transformation. The
log(x) values appear to have substantial left skewness but this is
attributable to a small number of values close to zero. In practice,
this transformation may also be considered. Thus, in the following
we describe the assessment of sample size using all of these
approaches.
Sample Size Computations
The power of the test of means depends on the absolute
difference between groups on the chosen scale, the sample size and
the residual variation as measured by the standard deviation (SD)
or root mean square error (RMSE) s. For a given type I error
probability a, residual RMSE (SD) s, and fraction of subjects
assigned to the treated group Q, equation (1) of the sub-section on
Statistical Computations provides the sample size N needed to
provide desired power 1{b to detect a difference D~m1{m2 in
the mean values on the chosen scale in the treated group and
control groups [14]. If no transformation was employed then D is
the difference in the untransformed or raw mean values. If a
transformation was employed then D is the difference in the means
of the transformed values.
Table 3 presents the quantities needed to compute sample size
or power for non-stratified analyses without or with a transfor-
Figure 1. Box plots showing the quartiles, the 5th and 95th percentiles (whiskers) and extreme values to the minimum and
maximum (o) of the raw AUC mean C-peptide values for all subjects at baseline and at months 6, 12, 18 and 24.
doi:10.1371/journal.pone.0026471.g001
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The table also presents the relevant quantities within three age
strata shown in Table 1 since the mean C-peptide values and
standard deviation vary according to age, as described below. The
baseline transformed and inverse mean is also presented for
reference. While the trial properties could be described in terms of
the change from baseline, as described in the methods, from [10]
in terms of changes from baseline would have the exact same
power as an analysis of the follow-up visit values when both
analyses are also adjusted for baseline. Thus, for simplicity,
computations are described in terms of the month 12 or 24 values,
not the changes from baseline.
Power depends on the difference between the means on the
chosen scale (i.e., without or with transformation), and the smaller
this difference the lower the power. Likewise, power depends on
the residual RMSE, and the higher the value the lower the power.
There is sampling variation in both of these quantities such that
the values in a future study could be higher or lower than those
observed herein, affecting power. Thus, more conservative
estimates of sample size and power are provided using the one-
sided lower 90% confidence limit for the mean and the upper 90%
limit for the SD. Table 4 then presents sample size computations
for an analysis at 12 and 24 months, respectively, using either the
non-transformed or transformed data assuming a one-sided test at
the 0.05 level, 85% power and a 2:1 allocation ratio (treated:con-
trol) with no losses to follow-up. These are the design parameters
adopted as a template for TrialNet studies; however, additional
computations with other design parameters are readily obtained
from the equations presented in the sub-section on Statistical
Computations. Also, to be conservative, in Table 4 the 90% lower
limit for the control group mean and upper limit for the RMSE
from Table 3 are employed. For an analysis of the raw AUC mean
values, there is no transformation so the difference between groups
(D) refers to a difference in the original units (pmol/ml). That
difference is often specified in terms of a percentage difference,
such as 50%. Alternately the difference could be specified in terms
of an algebraic difference (subtraction).
For example, in Table 4 the estimated untransformed mean at
12 months in the control group is 0.4 pmol/ml. A 50% increase
yields a mean of 0.6 in the treated group with D~0:2 pmol/ml.
With RMSE s~0:259, the standardized difference is D=s~0:77
with resulting N =53.0, rounded up to 54, the next highest
number divisible by 3. Alternately, the difference to be detected
could have been specified as an algebraic difference of 0.2 pmol/
ml, rather than a 50% increase, yielding the same result in this
case. However, in other cases shown, a 50% difference may not be
equivalent to a difference of 0.2 pmol/ml.
For sample size calculations where a transformation will be
employed, it is important to note that the analysis, and thus the
means and D (and the RMSE s), must be specified in terms of the
transformed values. However, the meaningful difference to be
detected is generally specified in terms of the inverse means in
pmol/ml. Consider, for example, detecting a 50% difference using
the log(xz1) transformation. The control group mean of the
log(xz1) values is 0.31 log(pmol/ml+1). The inverse control
group geometric-like mean is (exp0:31 {1)~0:36 pmol/ml. A
50% difference yields a value of 0.54 pmol/ml in the treated
group with a corresponding log(xz1) value of 0.43 log(pmol/
ml+1). Compared to the mean value of 0.31 log(pmol/ml+1) in the
control group, this yields D~(0:43{0:31)~0:12. When em-
ployed in equation (1) with RMSE s~0:167, the resulting
N =57.7 that is rounded to 60.
Table 1. Characteristics of the MMF/DZB study cohort and the Anti-CD20 Control Group.
MMF/DZB cohort Anti-CD20 control cohort Combined Cohort
N=126 N=30 N=156
Age (years) 18.7+9.6 17.3+7.8 18.4+9.3
8–12 years 37 (29%) 8 (27%) 45 (29%)
13–17 years 39 (31%) 13 (43%) 52 (33%)
18 years and older 50 (40%) 9 (30%) 59 (38%)
Sex (% male) 76 (60%) 18 (60%) 94 (60%)
Race (% white) 118 (94%) 29 (97%) 147 (94%)
Ethnicity (% Non-Hispanic) 119 (94%) 27 (90%) 146 (94%)
HbA1c (%) 7.6+1.3 7.1+1.3 7.5+1.3
Total insulin dose/kg 0.37+0.21 0.38+0.22 0.38+0.20
AUC Mean C-peptide (pmol/ml) 0.70+0.33 0.74+0.37 0.71+0.34
Time since diagnosis (days) 77+19 83+19 78+19
Number (%) of positive Autoantibodies
*
0 2 (2%) 1 (3%) 3 (2%)
1 21 (17%) 7 (23%) 28 (18%)
2 43 (34%) 11 (37%) 54 (35%)
3 60 (48%) 11 (37%) 71 (46%)
# Subjects with 2 h MMTT at each visit
Baseline 126 30 156
Month 12 122 30 152
Month 24 94 24 118
*Among ICA, GAD65, and ICA512.
doi:10.1371/journal.pone.0026471.t001
Sample Size for Studies in Early Type 1 Diabetes
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26471Alternately, the difference could be specified as an algebraic
difference in the inverse mean values, such as a 0.2 pmol/ml
difference in the geometric-like means. In this case the treated
group inverse mean would be 0.56 pmol/ml and the correspond-
ing log(xz1) value is 0.44. This yields a D~(0:44{0:31)~0:13
log(pmol/ml+1) and the resulting N =47.4 that is rounded to 48.
This smaller sample size arises because a 0.2 pmol/ml difference
between groups in the inverse means results in a larger D in the
transformed values (0.13) than when the effect is specified as a
50% improvement (0.12).
The sample size required to detect a 50% difference is larger using
the log(x) values than the other approaches because its corresponding
standardized difference D=s is smaller. The smaller the standardized
difference, the larger is the required sample size. Using the log(x)
transformation yields D~({0:9){({1:32)~0:42 log(pmol/ml) and
D=s~(0:42=0:818)~0:51,c o m p a r e dt oD=s~(0:12=0:167)~0:72
using the log(xz1).
The sample size required to detect a 50% difference at 24
months is double that needed to detect a 50% difference at 12
months. One reason is that the control group-mean is smaller, due
to the progressive loss of C-peptide leading to lower values at 24
than at 12 months, some of which are virtually zero (and still
included in the analysis). As a result, a 50% increase in the pmol/
ml values results in a slightly smaller difference D between the
transformed means at 24 than at 12 months, except for the log(x)
analysis that is unchanged from 12 months. But the main reason is
the higher RMSE at 24 months than at 12 months, more so for the
log(x), resulting in smaller standard difference values D=s and
larger N than at 12 months.
However, the sample size needed for a study designed to detect
a 0.2 pmol/ml difference between groups at month 24 is about the
same as that at month 12, except for the log(x). While the RMSE
of the log(x) is greater at 24 than 12 months, so also is the mean
difference so that the standard difference D=s is greater at 24
months, resulting in a smaller sample size requirement at month
24 than at month 12.
The sub-section on Statistical Computations also presents
equations for the computation of power for a given N using
Figure 2. Q-Q plots of the model residuals for untransformed AUC mean values from the combined studies separately at 12 (A) and
24 months (B). Based on the distribution of the residuals in an ANCOVA model adjusted for the baseline untransformed C-peptide value, age, sex,
study and treatment group.
doi:10.1371/journal.pone.0026471.g002
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can be detected with a given level of power with a specific s and
N.
Influence of Age
In Table 3, the residual SD values in the 13–17 year age
category are substantially higher than those in the other age strata
at 12 months but not at 24 months. Thus, a substantially larger
sample size would be required for a 12-month study in this age
group, or predominantly containing this age group, regardless of
whether the treatment effect of interest is stated as a percentage
difference or an absolute difference between groups.
Table 3 also shows that the control group mean values at 12 and
at 24 months are substantially higher in the 18+ year category
than in the other two strata. This indicates that a smaller sample
size would be required to detect a given percentage treatment
group difference within this age stratum than within other age
strata. The table, however, also presents the baseline transformed
and inverse means within each age stratum. Compared to the
month 12 and 24 values, the baseline values are also higher in the
18+ category than the 8–12 category. This indicates that the C-
peptide is declining at a lower rate in the 18+ year category and
that a smaller algebraic treatment group difference might therefore
be observed, thus requiring a larger sample size.
For illustration, Table 5 presents the sample size calculations for
a 12-month study restricted to each of the three age strata using
the log(xz1) values. To detect a 50% difference, a study in adults
would require a much smaller sample size, but to detect a
0.2 pmol/ml difference, a study in children 8–12 y would require
a smaller sample size. In both cases, a study restricted to
adolescents 13–17 y of age would require the largest sample size.
Age Mixtures
The TrialNet data herein consists of a mixture of subjects within
the three age categories as shown in Table 1 that applies to the
overall estimates presented in Table 3. However, the mixture of
the age groups within a study may differ from that herein, such as
for a study that is restricted to adults alone initially, followed by
enrollment of adolescents and adults. In this case, a sample size
computation could be based on a weighted average of the age
Figure 3. Q-Q plots of the model residuals for natural log-transformed AUC mean values from the combined studies separately at
12 (A) and 24 months (B). Based on the distribution of the residuals in an ANCOVA model adjusted for the log baseline C-peptide value, age, sex,
study and treatment group.
doi:10.1371/journal.pone.0026471.g003
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expected to fall within each age stratum. Details are presented in
the sub-section on Statistical Computations.
The Anti-CD20 Study Results
The anti-CD20 study published results demonstrated significant
differences between the rituximab and control group subjects in
the primary intent-to-treat analysis of the log(xz1) values at one
year of follow-up [6]. That single analysis was pre-specified in the
study protocol because any post-hoc selected analysis could
substantially inflate the type I error probability and lead to biased
results. Nevertheless, it is instructive to examine what the study
results would have been had a different approach to the analysis
been chosen.
Table 6 presents the ANCOVA model adjusted treatment
group effect using the untransformed and transformed 12-month
C-peptide values. As expected from above, the analysis of
untransformed values failed to reach statistical significance,
whereas those of the transformed values were each statistically
significant. While the log(x) analysis produced the smallest p-
value, its F-value was not substantially different from that of the
other analyses.
The distribution of the raw AUC mean residuals in this study was
not as distorted that in the combined cohort data. The distributions of
the transformed values were similar to those inthe combined cohorts.
The Shapiro-Wilks test was again significant for the raw and log(x)
values, but White’s test values were similar in the four analyses.
The log(x) or other transformation may produce different
variances between groups, thus violating one of the assumptions of
the ANCOVA test [15]. The F-test of equality of the variances of
the covariate-adjusted values was highly significant for the log(x)
transformed values (pv0:0001) and marginally for the
ﬃﬃﬃ
x
p
values
(p=0.046), but not the raw values or log(xz1) values. In this
case, Satterthwaite’s test, that allows for unequal variances, yields
p=0.017 for the difference between groups in the log(x) values,
and p=0.019 for the
ﬃﬃﬃ
x
p
values.
Two additional distribution-free tests of the difference in
baseline-adjusted values also provided significant results. A
Wilcoxon test (also called a rank transformation analysis [16])
provided one-sided p-values ranging from 0.023 to 0.029; and a
Figure 4. Q-Q plots of the model residuals for log(xz1) transformed AUC mean values from the combined studies separately at 12
(A) and 24 months (B). Based on the distribution of the residuals in an ANCOVA model adjusted for the baseline log (C-peptide+1) value, age, sex,
study and treatment group.
doi:10.1371/journal.pone.0026471.g004
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variance [13] yielded p-values almost identical to those in Table 6
(0.061, 0.008, 0.018 and 0.012, respectively).
Thus, even though the log(x) distribution departs from normality, it
nevertheless provides a significant difference between groups as did the
other transformations. Were the log(x) analysis pre-specified as the
primary analysis, the result would still be valid, though the test would
have less power than one using a more appropriate transformation.
Table 7 then shows the inverse means and the relative and absolute
differences between groups on each scale. Among the different
analyses, the percentage difference in the inverse means was greatest
for the log(x) values even though the control group mean was lower.
The algebraic differences were similar among the analyses. Table 6
shows the transformed means, the RMSE and the standardized
difference for each analysis. The standardized difference that
determines power is slightly greater for the log(x) values.
Statistical Computations
This sub-section presents the statistical equations used in the
computations presented in the main paper, with additional
examples. This includes methods for the calculation of sample
size and power; the assessments based on different mixtures of
subjects in the three age strata; and the computation of a ratio or
difference in the mean levels using either the log(x+1) or square
root transformations. Throughout, the C-peptide value x refers to
the AUC mean value in pmol/ml.
Computation of Sample Size and Power. The equations
used to compute sample size and power are widely available, as in
[14]. Let a denote the type 1 (false positive) error probability and b
the type II (false negative) error probability. Then Z1{a is the
critical value for the test statistic at level a, one or two-sided as pre-
specified; e.g. Z1{a~1:645 for a one-sided 0.05 level test, 1.96 for
a two-sided test. Z1{b is the quantile corresponding to the desired
level of power 1{b, e.g. 1.04 for 85% power. To allow for an
unequal allocation, let Q designate the fraction of subjects assigned
to the treated group, 1{Q that to control, e.g. Q~2=3 for a 2:1
randomization to treatment and control. Then let m1 denote the
mean of the transformed (or untransformed) values in the treated
group and m2 that in the control group, with difference
D~m1{m2. Denote the root mean square error (RMSE) of the
Figure 5. Q-Q plots of the model residuals for square-root transformed AUC mean values from the combined studies separately at
12 (A) and 24 months (B). Based on the distribution of the residuals in an ANCOVA model adjusted for the baseline square-root C-peptide value,
age, sex, study and treatment group.
doi:10.1371/journal.pone.0026471.g005
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difference D in the transformed values is provided by the equation
N%
(Z1{azZ1{b)s
D
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Q(1{Q)
p
"# 2
ð1Þ
where % designates approximate equality.
To allow for a fraction (L) losses-to-follow-up or missing
outcome data, then the sample size would inflated by (1{L)
{1.
For example, if N~100 with complete follow-up, then to adjust
for 20% losses the sample size would be inflated to yield
NL~N=(1{L)~100=0:8~125.
In some cases, the sample size may be specified from other
considerations and it may then be desired to evaluate the power of
the study to detect a given difference. In this case, for a given N
the power is computed from
Z1{b%
D
s
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NQ(1{Q)
p
{Z1{a ð2Þ
where power=W(Z1{b) is the cumulative normal fraction at the
value Z1{b, e.g. power=0.85 for Z1{b =1.04. Alternately, the
study properties may be specified in terms of a difference D that
can be detected with a given level of power with a specific Nand s,
as provided by
D%
(Z1{azZ1{b)s
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NQ(1{Q)
p : ð3Þ
The N employed in equations (2) and (3) should be the number of
evaluable subjects. For example, if the planned N~200, to allow
for 10% losses, then the equation should employ N~180.
The above simple equations are approximations to the precise
computations using the non-central student’s t-distribution for
which iterative computations are required. See [14], among many.
ForNw100 the precisesample size is less than 2%greater than that
provided by the above equation (1), and less than 1% for Nw200.
For example, Table 4 shows that a sample size of N =60
provides 85% power to detect a 50% difference using the
log(xz1) transformed values at 12 months, whereas a sample
size of 117 would be required at 24 months. If the study is
conducted using N=60, the power to detect a 50% difference at
24 months could be computed using (2). From Table 4, a 50%
difference in a log(xz1) analysis at 24 months would yield a value
D=s=0.52. Substituting this quantity along with N~60 yields
Z1{b =0.254 that corresponds to power of 60%.
Alternately, the difference that can be detected with 85% power
could be computed from (3) upon substituting Z1{b =1.04(for85%
power), s=0.192(theRMSEfromTable4)andN~60 to show that
this sample size would provide 85% power to detect a difference
D=0.14inthelog(xz1) values at 24 months. Adding this amount
to the control transformed mean in Table 4 (0.23) yields a treated
transformed mean of 0.24+0.14=0.38. Taking the inverse transfor-
mation of each yields means of 0.27 pmol/ml for the control group
and 0.46 pmol/ml for the treated group, or a 70% difference.
Age-Averaged Estimation. As described in the text, other
studies may comprise a mixture of age categories that differs from
that in the TrialNet studies. Denote the fraction of subjects within
the three age categories as P1 for age 8–12, P2 for 13–17, and P3
for 18 and older. For a specified difference between groups, that
could vary among the age strata, let Di denote the difference to be
detected within the ith age stratum, and si the residual standard
deviation within each stratum (i~1,2,3). Then, the average
expected difference between groups is
D~
X3
i~1 PiDi ð4Þ
and the average residual variance would be
P3
i~1 Pis2
i . Then
sample size would be computed using
N~
(Z1{azZ1{b)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P3
i~1 Pis2
i
q
P3
i~1 PiDi
   ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Q(1{Q)
p
2
4
3
5
2
: ð5Þ
Likewise, the power of the study for a given sample size would be
obtained from
Z1{b~
P3
i~1 PiDi ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P3
i~1 Pis2
i
q
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NQ(1{Q)
p
{Z1{a ð6Þ
and the average difference that can be detected as
D~
(Z1{azZ1{b)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P3
i~1 Pis2
i
q
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NQ(1{Q)
p ð7Þ
For example, consider a study designed to detect a 50%
difference using the log(xz1) transformed values in an analysis at
12 months that is projected to enroll fractions P1~0:4, P2~0:4,
and P3~0:2. From the quantities specified in Table 3, a 50%
increase in the 90% limit of the inverse control group means, the
resulting transformed means, and D are
Stratum
(i)
Control
Inverse
Mean
(pmol=ml)
Treated
Inverse
Mean
(pmol=ml)
Control
In(Meanz1)
Treated
In(Meanz1)
Di
10 :25 0:375 0:22 0:32 0:10
20 :30 0:45 0:26 0:37 0:11
30 :49 0:735 0:40 0:55 0:15
Table 2. p-values for the Shapiro-Wilks test of departures
from normality and White’s test of homoscedasticity for
analyses of the AUC mean C-peptide at 12 and 24 months
without or with transformations after adjustment for age and
sex at baseline, study and treatment group, and the baseline
value on the same scale (i.e. non-transformed or transformed
the same as the follow-up values).
Month 12 Month 24
Shapiro-Wilks White
Shapiro-
Wilks White
AUC mean (x) 0.0102 0.0065 0.0413 0.4599
log(x) v0.0001 0.6646 0.0033 0.2844
log(xz1) 0.9010 0.0193 0.4907 0.2820
ﬃﬃﬃ
x
p
0.4810 0.2122 0.8418 0.1987
doi:10.1371/journal.pone.0026471.t002
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values at 12 or 24 months, along with the baseline mean values (transformed and inverse).
A. 12 months, combined cohort control group
Baseline Mean Transformed Inverse Residual SD
Transf. Inverse Mean 90% limit mean 90% limit RMSE 90% limit
AUC mean (x)
Overall 0.71 0.71 0.42 0.40 0.42 0.40 0.239 0.259
Age 8–12 y 0.63 0.63 0.29 0.26 0.29 0.26 0.174 0.206
Age 13–17 y 0.75 0.75 0.35 0.31 0.35 0.31 0.250 0.291
Age 18+ y 0.73 0.73 0.57 0.53 0.57 0.53 0.244 0.288
log(x)
Overall 20.46 0.63 21.24 21.32 0.29 0.27 0.755 0.818
Age 8–12 y 20.59 0.56 21.64 21.78 0.19 0.17 0.741 0.876
Age 13–17 y 20.35 0.71 21.38 21.55 0.25 0.21 0.927 1.079
Age 18+ y 20.47 0.63 20.80 20.88 0.45 0.41 0.477 0.549
log(xz1)
Overall 0.52 0.68 0.33 0.31 0.39 0.36 0.154 0.167
Age 8–12 y 0.47 0.60 0.24 0.22 0.27 0.25 0.120 0.142
Age 13–17 y 0.55 0.73 0.29 0.26 0.34 0.30 0.175 0.204
Age 18+ y 0.52 0.69 0.42 0.40 0.52 0.49 0.147 0.169
ﬃﬃﬃ
x
p
Overall 0.82 0.67 0.60 0.58 0.36 0.34 0.183 0.198
Age 8–12 y 0.77 0.59 0.50 0.47 0.25 0.22 0.153 0.181
Age 13–17 y 0.85 0.73 0.55 0.51 0.30 0.26 0.215 0.250
Age 18+ y 0.82 0.68 0.71 0.68 0.50 0.46 0.160 0.184
B. 24 months, combined cohort control group
Baseline Mean Transformed Inverse Residual SD
Transf. Inverse Mean 90% limit mean 90% limit RMSE 90% limit
AUC mean (x)
Overall 0.72 0.72 0.34 0.31 0.34 0.31 0.265 0.291
Age 8–12 y 0.63 0.63 0.19 0.15 0.19 0.15 0.168 0.205
Age 13–17 y 0.73 0.73 0.25 0.21 0.25 0.21 0.226 0.268
Age 18+ y 0.79 0.79 0.55 0.48 0.55 0.48 0.370 0.441
log(x)
Overall 20.42 0.66 21.70 21.82 0.18 0.16 1.036 1.136
Age 8–12 y 20.55 0.58 22.24 22.49 0.11 0.08 1.115 1.361
Age 13–17 y 20.37 0.69 21.91 22.13 0.15 0.12 1.144 1.355
Age 18+ y 20.36 0.70 21.04 21.21 0.35 0.30 0.865 1.031
log(xz1)
Overall 0.53 0.69 0.26 0.24 0.30 0.27 0.175 0.192
Age 8–12 y 0.48 0.61 0.17 0.14 0.19 0.15 0.128 0.156
Age 13–17 y 0.54 0.71 0.21 0.18 0.23 0.20 0.166 0.197
Age 18+ y 0.56 0.75 0.40 0.35 0.49 0.42 0.227 0.270
ﬃﬃﬃ
x
p
Overall 0.83 0.69 0.51 0.48 0.26 0.23 0.218 0.239
Age 8–12 y 0.78 0.60 0.39 0.35 0.15 0.12 0.184 0.225
Age 13–17 y 0.84 0.71 0.45 0.41 0.20 0.17 0.222 0.263
Age 18+ y 0.86 0.74 0.67 0.62 0.45 0.38 0.257 0.306
The one-sided lower 90% confidence limit for the control group mean and the upper 90% limit for the root mean square error (RMSE) are also
shown.
doi:10.1371/journal.pone.0026471.t003
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X3
i~1 PiDi~D~(0:4|0:10)z(0:4|0:11)
z(0:2|0:15)~0:112
ð8Þ
X3
i~1 Pis2
i ~(0:4|0:1422)z(0:4|0:2042)
z(0:2|0:1692)~0:0304
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ﬃ
X3
i~1 Pis2
i
r
~s~0:174
Interpretation of log(x) and log(x+1) Analyses. For an
analysis of the raw values, standard programs will compute the
baseline adjusted mean values and their differences. For an
analysis on the log scale, taking the exponential function of the
baseline adjusted means provides estimates of the geometric
means. Programs also provide an estimate of the difference
between the means of either the raw values or the log values. In
the latter case, taking the exponential function of the difference
provides an estimate of the ratio of the geometric means.
However, for an analysis using the log(x+1) transformation or the
square root transformation, programs do not directly provide estimates
of the ratio or difference of the corresponding C-peptide mean values
on the pmol/ml scale. Herein we show how these estimates can be
obtained from other computer program computations.
If the log(x+1) transformation is used as the basis for the analysis
of the levels of C-peptide it is useful to summarize the results using
the ratio of the geometric means, say R, with 95% confidence
limits on R. Since R is a ratio with a value of 1 under the null
hypothesis, asymmetric confidence limits computed using the log
of R will provide more accurate coverage probability than
symmetric limits based on the simple estimated standard error of
R itself. The necessary quantities can be obtained from an analysis
of the log(x+1) values using a program such as a SAS PROC GLM
or PROC MIXED to compute the adjusted means (called
LSmeans) and their standard errors.
Table 4. Sample sizes* for two groups with 2:1 allocation (Q=2/3) to treatment versus control needed to provide 85% power to
detect either a 50% difference, or an absolute difference of 0.2 pmol/ml, using either the raw or transformed data for an
unstratified analysis at 12 or at 24 months.
Analysis at 12 months
Inverse Mean (pmol/ml) Transformed Mean
Control Treated Control Treated D RMSE sD =s N
50% difference
AUC mean (x) 0.4 0.6 – – 0.20 0.259 0.77 53.0 (54)
log(x) 0.27 0.41 21.32 2.90 0.42 0.818 0.51 131.0 (132)
log(xz1) 0.36 0.54 0.31 0.43 0.12 0.167 0.72 57.7 (60)
ﬃﬃﬃ
x
p
0.34 0.51 0.58 0.71 0.13 0.198 0.66 73.1 (75)
0.2 pmol/ml Difference
AUC mean (x) 0.4 0.6 – – 0.20 0.259 0.77 53.0 (54)
log(x) 0.27 0.47 21.32 20.76 0.56 0.818 0.68 70.1 (72)
log(xz1) 0.36 0.56 0.31 0.44 0.13 0.167 0.78 47.4 (48)
ﬃﬃﬃ
x
p
0.34 0.54 0.58 0.73 0.15 0.198 0.76 54.5 (57)
Analysis at 24 months
Inverse Mean (pmol/ml) Transformed Mean
Control Treated Control Treated D RMSE sD =s N
50% difference
AUC mean (x) 0.31 0.47 – – 0.16 0.291 0.55 114 (114)
log(x) 0.16 0.24 21.83 21.43 0.40 1.136 0.35 254 (255)
log(xz1) 0.27 0.41 0.24 0.34 0.10 0.192 0.52 116.9 (117)
ﬃﬃﬃ
x
p
0.23 0.35 0.48 0.59 0.11 0.239 0.46 159.1 (162)
0.2 pmol/ml Difference
AUC mean (x) 0.31 0.51 – – 0.20 0.291 0.69 68.5 (69)
log(x) 0.16 0.36 21.83 21.02 0.81 1.136 0.71 63.5 (66)
log(xz1) 0.27 0.47 0.24 0.39 0.15 0.192 0.78 55.8 (57)
ﬃﬃﬃ
x
p
0.23 0.43 0.48 0.66 0.18 0.239 0.75 59.6 (60)
*All computations are for a one-sided test at the 0.05 level with no adjustment for losses to follow-up. In all cases the 90% limits for the control group mean and the SD
are used as the parameter values in equation (1). The exact N is provided as well as that rounded up to the nearest integer satisfying the 2:1 allocation fractions.
doi:10.1371/journal.pone.0026471.t004
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group (i~1,2). Then R is expressed as
R~
ey1{1
ey2{1
ð9Þ
and the log geometric mean ratio L~log(R) as
L~log
ey1{1
ey2{1
  
~log(ey1{1){log(ey2{1): ð10Þ
The variances of each mean, say Var(y1)~V1 and V(y2)~V2,
are provided by squaring the standard errors provided by the
LSMEANS computation. An additional computation is needed to
obtain the covariance of the two.
The LSMEANS output also includes a computation of the
difference, i.e. D~y1{y2, but not the SE of the difference. Thus,
an estimate statement is used to obtain the variance (or SE) of the
difference between the group LSmeans. Since
Var(D)~Var(y1)zVar(y2){2Cov(y1,y2) ð11Þ
then the covariance, say Cov(y1,y2)~Cov1,2, is obtained by
subtraction as
Cov1,2~
V1zV2{Var(D)
2
: ð12Þ
Using the delta method it is then shown that the variance of the log
ratio is
V(L)~VL~
ey1
ey1{1
  
V1z
ey2
ey2{1
   2
V2{ 2
ey1
ey1{1
  
ey2
ey2{1
  
Cov1,2:
Table 5. Sample sizes* for two groups with 2:1 allocation (Q=2/3) to treatment versus control needed to provide 85% power to
detect either a 50% difference, or an absolute difference of 0.2 pmol/ml, using an age-stratified analysis of log(x+1) values at 12
months.
Analysis at 12 months using the log(xz1) values with three age strata
Inverse Mean (pmol/ml) Transformed Mean
Control Treated Control Treated D RMSE sD =s N
50% difference
Age 8–12 y 0.25 0.375 0.22 0.32 0.10 0.142 0.70 87.5 (90)
Age 13–17 y 0.30 0.45 0.26 0.37 0.11 0.204 0.54 139.6 (141)
Age 18+ y 0.49 0.735 0.40 0.55 0.15 0.169 0.89 51.8 (54)
0.2 pmol/ml Difference
Age 8–12 y 0.25 0.45 0.22 0.37 0.15 0.142 1.06 28.3 (30)
Age 13–17 y 0.30 0.50 0.26 0.41 0.15 0.204 0.74 62.0 (63)
Age 18+ y 0.49 0.69 0.40 0.52 0.12 0.169 0.71 51.8 (54)
*All computations are for a one-sided test at the 0.05 level with no adjustment for losses to follow-up. In all cases the 90% limits for the control group mean and the SD
are used as the parameter values in equation (1). The exact N is provided as well as that rounded up to the nearest integer satisfying the 2:1 allocation fractions.
doi:10.1371/journal.pone.0026471.t005
Table 6. Analysis of covariance (ANCOVA)
* of the difference between the rituximab versus control groups in the distributions of
AUC mean values at 12 months of follow-up without and with transformations adjusted for age and sex and the baseline value.
Rituximab Control
Transformed Transformed Standardized F-
mean (95% CI) mean (95% CI) Difference RMSE Difference value p-value
N=49 N=29
{
AUC mean (x) 0.604 0.531 0.073 0.248 0.294 1.53 0.11
log(x) 20.736 21.096 20.360 0.613 0.587 6.12 0.008
log(xz1) 0.445 0.383 0.063 0.141 0.447 3.48 0.03
ﬃﬃﬃ
x
p
0.737 0.657 0.079 0.161 0.491 4.32 0.021
*In each analysis, the like-transformed (or untransformed) baseline AUC mean value was employed as an adjusting covariate, e.g. log(xz1) of the baseline value in the
analysis of the log(xz1) 12 month values. The means of the transformed (or untransformed) values within groups, and the difference, are presented along with the root
mean square error (RMSE) of those values, the standardized difference, the F-value and one-sided p-value for the effect of treatment.
{These analyses are based on the intention-to-treat cohort that includes 29 placebo-treated subjects who met the defined criteria. The results using the log(xz1) values
are identical to those that appeared in the primary study manuscript [6].
doi:10.1371/journal.pone.0026471.t006
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exp L+Z0:975
ﬃﬃﬃﬃﬃﬃ
VL
p hi
: ð13Þ
Interpretation of
ﬃﬃﬃ
x
p
Analyses. If the analysis uses the
ﬃﬃﬃ
x
p
transformation it would be desirable to summarize the results
using the difference of the inverse means, say S, with 95%
confidence limits on S, both computed in pmol/ml units. As
above, let y1 refer to the LSmean of
ﬃﬃﬃ
x
p
in one group and y2 that
in the other group, with respective variances V1 and V2 obtained
as the square of the standard errors. Then the difference S in
pmol/ml units is expressed as
S~y2
1{y2
2: ð14Þ
Again using the delta method, the variance of S is obtained as
V(S)~VS~ 2y1 ½ 
2V1z 2y2 ½ 
2V2{24 y1y2 ½  Cov1,2:
The 95% symmetric confidence limits on S are then obtained as
S+Z0:975
ﬃﬃﬃﬃﬃﬃ
VS
p
: ð15Þ
Discussion
Analyses of two recently completed TrialNet studies in newly
diagnosed type 1 diabetes assess the properties of the stimulated C-
peptide levels of a 2-hour Mixed Meal Tolerance Test used to
measure b-cell function. In general, a transformation is needed to
improve the normality of the distribution of values. Among those
considered herein, the log(x) over-corrects, replacing right
skewness with left skewness, whereas the log(xz1) and
ﬃﬃﬃ
x
p
values
are more nearly symmetrically distributed. The resulting sample
size estimates for an analysis using the log(x) values are greater
than using either the raw or log(xz1) and
ﬃﬃﬃ
x
p
values. The sample
sizes using the
ﬃﬃﬃ
x
p
values were slightly greater than those using the
log(xz1) values.
TrialNet pre-specified that the log(xz1) transformation would
be used so as to improve the distribution because the majority of
the AUC mean values are less than 1 [3]. Another approach to
deal with this might be to simply multiply the AUC mean values
(x) by a constant (C), such as multiplying by C~100 to yield
values 100*AUC mean in pmol/(ml/100). Taking the log
transformation yields log(cx)~log(c)zlog(x). In this case the
shape of the distribution of log(cx) is the same as that of log(x)
and the properties of the analysis of the log(cx) values is the same
as that of an analysis of the log(x) values.
While TrialNet had initially selected the log(xz1) transforma-
tion based on its preliminary data, it is possible that preliminary
studies of a compound might suggest that a different transforma-
tion best captures the effect of treatment on the distribution of
values. For example, if a preliminary study suggests that an
analysis of the raw values appears to best reflect the treatment
group difference, then a sample size calculation using the raw
values might be preferred even though, based on the computations
herein, a smaller sample size might be computed using a
transformation. Likewise, preliminary data from other studies
might suggest that a different transformation, like log(x), might be
preferred, in which case we hope that the data presented herein
could be useful for planning future studies.
Sample size computations are shown for an analysis at 12 and
24 months using either a relative (50%) increase or a fixed
(0.2 pmol/ml) difference between groups. The N required to
detect a fixed difference is principally a function of the residual
variation (RMSE) that tends to be greater at 24 than at 12 months,
resulting in a larger N at 24 months. The N required to detect a
relative increase is also a function of the control group mean
because a percentage increase from a larger control mean value
equates to a larger absolute difference. For example, in Table 4, a
50% increase in the log(xz1) values at 12 months corresponds to
a difference of 0.12 pmol/ml versus a difference of 0.10 pmol/ml
at 24 months in Table 4, again resulting in a larger N at 24
months.
In practice it might be more appropriate to consider a larger
difference between groups at 24 than at 12 months. For example,
if an effective treatment actually stabilized the level of C-peptide
over 2 years, then owing to the progressive decline in the control
group, there should be a larger difference between groups at 24
than at 12 months that would lead to the requirement for a smaller
sample size.
The results also depended on age, stratified herein as 8–12
years, 13–17 and 18 and older at diagnosis. The residual variation
among those 13–17 years was substantially higher than that in the
other age categories, perhaps because they are peripubertal. Thus,
methods are described to compute sample size for a study with
specific planned fractions of subjects in these age categories.
It may also be prudent to consider different effect sizes within
the age strata. Comparing the inverse mean values within the age
strata at 12 months versus 24 months (Table 3), the rate of decline
in those 18 and above is less than that in the other categories.
Thus, a treatment that stabilizes the level of C-peptide over 2 years
would have a smaller treatment effect among those 18 and above
because the control group would be falling at a lower rate. This
could readily be addressed by using a smaller difference in this age
category when conducting an age specific computation as shown
in the sub-section on Statistical Computations.
The TrialNet anti-CD20 study showed a statistically significant
beneficial effect (p=0.02) of rituximab versus placebo on the pre-
Table 7. For each ANCOVA in Table 6*, the inverse-
transformed means (pmol/ml) are presented along with 95%
confidence limits, the algebraic difference and the percentage
difference.
Rituximab Control Difference
Inverse mean
Inverse
mean
(95% CI) (95% CI) Algebraic %
AUC mean (x) 0.60 0.53 0.07 13%
(0.53, 0.68) (0.44, 0.62)
log(x) 0.48 0.33 0.15 45%
(0.40, 0.57) (0.27, 0.42)
log(xz1) 0.56 0.47 0.09 20%
(0.50, 0.63) (0.39, 0.55)
ﬃﬃﬃ
x
p
0.54 0.43 0.11 26%
(0.47, 0.61) (0.36, 0.51)
*These analyses are based on the intention-to-treat cohort that includes 29
placebo-treated subjects who met the defined criteria. The results using the
log(xz1) values are identical to those that appeared in the primary study
manuscript [6].
doi:10.1371/journal.pone.0026471.t007
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analyese presented herein show that the differences in the log(x)
and
ﬃﬃﬃ
x
p
, but not the raw, values were also statistically significant,
more so for the log(x). While the log(x) violated the common
variance assumption based on White’s test being significant
(Table 2), other non-parametric or robust tests not requiring that
assumption were also significant. Such a test might be preferred if
it is decided to use the log(x) values in the analysis of a study.
The optimal transformation may also differ for other methods of
analysis. For example, a secondary analysis of the anti-CD20 study
assessed the difference between groups in the average rate of
decline (or slope) in the C-peptide values over time [6].
Biologically, a constant percentage decline per year in C-peptide
would be expected [3], corresponding to the rate of decline in b-
cell mass. This constant percentage decline implies that the slope
of the log(x) values is constant over time, or that the log C-peptide
is a linear function of time with coefficient b, and the percentage
change in C-peptide per year is estimated as 100(exp(b){1).
Neither an analysis of the log(xz1) nor
ﬃﬃﬃ
x
p
values would have
this interpretation. On this basis, the log(x) values were employed
in the slope analysis presented in the published report [6]. This
analysis used a random coefficient model [17] allowing a unique
rate of change in log C-peptide over time for each subject with an
estimate of the mean slope within each treatment group. The
mean percentage decline in the rituximab group was significantly
less than that with placebo (38 versus 56% per year, p=0.027).
However, had the analysis been done using the raw, log(xz1) or ﬃﬃﬃ
x
p
values, none would have approached significance (pw0:155
for all).
It should also be noted that there are many other possible
transformations that might be employed. Among the most general
is the family of Box-Cox power transformations [18,19] that can
often transform a set of quantitative values to a near normal
distribution. Such transformations are often used to promote a
strongly linear association among variables on the transformed
scales. Rarely, however, are such transformations used for
inferences about the underlying mean values, as is the focus
herein.
Clearly, the results herein largely apply to a population of
subjects recruited in North America. Whether they apply to
studies conducted in other populations is unknown. However, the
distributions of C-peptide values obtained from a cross sectional
study of the properties of a mixed meal versus glucagon
stimulation test conducted in North America were similar to
those of an identical study conducted in Europe [4], despite the
fact that different central laboratories were employed in each
study. Further, it is remarkable that consistent patterns of change
in C-peptide over time have been observed in the control groups of
studies conducted different populations [6,7,20–23].
In conclusion, these TrialNet studies support the need to
employ a transformation in the analysis of C-peptide values over
time in therapeutic studies of new onset type 1 diabetes. The
patterns of variation differ after 12 months and 24 months, and
among age categories. However, it is possible to fine-tune the
design of a study in a manner that allows for these factors.
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